Autres langues OncoTherapy Science, Inc.

Actions

4564

JP3202150003

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
21,00 ^JPY	0,00%		0,00%	+5,00%

29/04/24	Le Premier ministre polonais Tusk appelle le procureur au sujet du scandale potentiel d'Orlen	RE
12/05/23	OncoTherapy Science, Inc. annonce ses résultats pour l'exercice clos le 31 mars 2023	CI

Autres langues

24/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt
28/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited
10/04/25	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding
14/05/24	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
29/04/24	Poland's Tusk calls prosecutor over potential Orlen scandal
22/04/24	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024
05/04/24	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor
05/12/23	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.
18/09/23	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index
12/05/23	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
10/04/23	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding
24/03/23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding
13/09/22	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer
28/04/21	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm
12/04/21	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm
01/10/20	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine
15/01/19	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.
26/12/18	OncoTherapy Science, Inc. announced that it expects to receive ¥12.013 million in funding from Daiwa Securities Group Inc.
14/07/17	Oncotherapy Science, Inc. and Theragen Etex Co.,Ltd., to Form Joint Venture Company
29/06/15	OncoTherapy Science, Inc.(TSE:4564) added to Russell Global Index
31/07/13	OncoTherapy Science, Inc. Signs Licensing Agreement with Societe d'Exploitation de Produits pour les Industries Chimiques S.A
02/04/12	Shionogi & Co. Signs Agreement with OncoTherapy Science Inc. for Cancer Peptide Vaccines